Recent Articles in Featured Companies

Prenetics, an HK-based genetic testing and digital health company, announced acquisition of DNAFit, a UK-based genetic testing company. DNAFit will bring in B2C channel, adding to the B2B channel that Prenetics currently possesses. This is the first acquisition Prenetics announced after it receiving $50 million from Alibaba Hong Kong Entrepreneurs Fund and Ping An Insurance. More details....

Share this with colleagues:  

Royal Philips and Digital China Health launched a cloud-based imaging diagnostic assisting platform called SHINEFLY. It makes an integrated clinical imaging diagnostic platform – IntelliSpace Portal 9.0 available through long distance control, and thus providing a tiered solution pricing for various levels of clinical institutions. More details....

Stock Symble: (NYSE: PHG, AEX: PHIA) 

Share this with colleagues:  

Denovo Biopharma, a San Diego-Hangzhou company,  has started a pivotal Phase III trial of its lead drug, DB102 (enzastaurin). DB102, which was initially developed by Eli Lilly, failed a Phase III clinical trial in 2013 in patients with diffuse large B-cell lymphoma (DLBCL). Denovo acquired global rights to DB102 in 2014, planning to redevelop the drug by targeting a sub-set of patients. By analyzing Lilly’s patient samples, Denovo found overall survival was significantly improved for patients who possess the DGM1 biomarker. The study will enroll 235 patients in the US and China. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

Shanghai Fosun Pharma plans to become the “Huawei of the pharmaceutical industry,” according to Qiyu Chen, Chairman of the company. Chen made the comparison because, like the China smartphone company, Fosun will continue to invest in R&D and pursue M&A while it plans further expansion into global markets. Last year, Fosun spent $239 million on R&D, part of the nearly $740 million it has spent over the last five years. And it completed a $1.1 billion acquisition of a majority stake in India's Gland Pharma, which it says will help Fosun market biosimilar drugs globally. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues: